GENFIT S.A. - American Depositary Shares (GNFT)
GNFT moved a median of 0.00% 30 minutes after news, and -0.53% by the close. How GNFT actually reacts to news — the realized, point-in-time move the market made, measured across 105 labeled events over the last three years with zero look-ahead.
GNFT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 19% | 75 |
| 30-min | 0.00% | 33% | 86 |
| 60-min | 0.00% | 46% | 92 |
| to close | -0.53% | 29% | 101 |
| Middle 50% of GNFT reactions | -0.55% to +0.25% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 105 |
Half of all GENFIT S.A. - American Depositary Shares news events land between -0.55% and +0.25% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when GNFT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to GNFT's baseline. Nothing else.
Recent GNFT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025 | Press release | GlobeNewswire | +0.00% | -0.48% | |
| GENFIT Announces Discontinuation of its VS-01 Program in ACLF: VS-01 Development Refocused on UCD | Press release | GlobeNewswire | -1.76% | +4.53% | |
| Genfit: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial | Press release | GlobeNewswire | +0.00% | -0.13% | |
| GENFIT to receive a €26.5 million milestone payment following the approval of pricing and reimbursement of Ipsen’s Iqirvo® in Italy | Press release | GlobeNewswire | +0.00% | -3.97% | |
| GENFIT to Present Latest ACLF Research at EASL Congress 2025 | Press release | GlobeNewswire | -0.22% | -0.22% | |
| GENFIT Announces Publication of the 2024 Universal Registration Document and the 2024 Annual Report on Form 20-F | Press release | GlobeNewswire | — | +0.25% | |
| GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025 | Press release | GlobeNewswire | +0.00% | +3.05% | |
| GENFIT Reports Full-Year 2024 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | -1.09% | |
| Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs | Press release | GlobeNewswire | — | -2.19% | |
| GENFIT Announces Revenues and Cash Position as of December 31, 2024 | Press release | GlobeNewswire | -0.55% | -4.14% | |
| GENFIT Announces the Preliminary Results of the Repurchase Offer to 2025 OCEANEs holders and the Convening of the 2025 OCEANEs holders’ general meeting | Press release | GlobeNewswire | -0.51% | -1.79% | |
| GENFIT Announces the Amendment of the Final Terms of the Dual Proposal to the 2025 OCEANEs Holders | Press release | GlobeNewswire | +0.75% | -3.02% | |
| GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders | Press release | GlobeNewswire | +0.00% | +0.26% | |
| GENFIT Announces Non-Dilutive Royalty Financing Agreement and Debt Overhang Resolution Plan | Press release | GlobeNewswire | +0.00% | -0.75% | |
| GENFIT Announces 2025 Financial Calendar | Press release | GlobeNewswire | +0.00% | -0.75% | |
| GENFIT: Ipsen’s Iqirvo® (Elafibranor) Receives EU Approval as a First-in-Class Treatment for Primary Biliary Cholangitis following U.S. FDA Accelerated Approval | Press release | GlobeNewswire | +0.60% | -0.20% | |
| GENFIT Reports First Half-Year 2024 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +2.41% | -2.62% | |
| GENFIT: Positive Opinion from EMA Committee for Ipsen’s Iqirvo® (elafibranor) in Primary Biliary Cholangitis | Press release | GlobeNewswire | — | -11.67% | |
| GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+® as Key Tool for Detecting At-Risk MASH | Press release | GlobeNewswire | +0.00% | +0.00% | |
| GENFIT: Historic Milestone Achieved with U.S. FDA Accelerated Approval of Ipsen’s Iqirvo® for Primary Biliary Cholangitis | Press release | GlobeNewswire | -0.73% | -5.48% | |
| GENFIT to Present Latest ACLF Research at EASL Congress™ 2024 | Press release | GlobeNewswire | +0.52% | +2.07% | |
| GENFIT: May 22, 2024 Combined Shareholders Meeting Results | Press release | GlobeNewswire | — | +0.00% | |
| GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023) | Press release | GlobeNewswire | +0.00% | +0.00% | |
| GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.00% | +3.17% | |
| GENFIT Announces 2024 Financial Calendar | Press release | GlobeNewswire | -0.84% | -3.76% | |
| GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials | Press release | GlobeNewswire | +1.45% | +1.43% | |
| GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023 | Press release | GlobeNewswire | — | -1.51% | |
| GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine | Press release | GlobeNewswire | +0.35% | -2.02% | |
| GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023 | Press release | GlobeNewswire | +0.00% | -3.40% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the GNFT section they belong to.
Where else GNFT is measured.
GNFT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is GENFIT S.A. - American Depositary Shares's median reaction calculated?
Every labeled GNFT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 105 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 33% of GNFT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does GNFT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.